Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlimid Trial in Multiple Myeloma Ends Enrollment Early

This article was originally published in The Pink Sheet Daily

Executive Summary

Positive results in trial of newly diagnosed patients could further support first-line indication.

You may also be interested in...



sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market

If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.

sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market

If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.

Millennium Will Submit Velcade sNDA For First-Line Use In Multiple Myeloma By Year End

Strong Phase III data presented at American Society of Hematology meeting could put Velcade ahead of Celgene’s Revlimid in the front-line race.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel